Tag: Crossject
Crossject: success of the capital increase
(CercleFinance.com) – Crossject announced last night the success of its capital increase of around eight million euros, mainly intended for the continued development of its needle-free auto-injector against epileptic seizures.…
Crossject: Success of the capital increase
Read also (CercleFinance.com) – Crossject announced last night the success of its capital increase of around eight million euros, mainly intended for the continued development of its needle-free auto-injector against…
Crossject announces the great success of its capital increase of 8 million euros – 06/04/2024 at 7:30 p.m.
Crossject, a specialty pharmaceutical company in the advanced clinical and regulatory development phase of ZEPIZURE®, an emergency treatment for the management of epileptic seizures based on the award-winning ZENEO® needle-free…
Crossject: Hailed for extended Zepizure deal
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Crossject: hailed for an extended agreement on Zepizure – 05/03/2024 at 2:23 p.m.
(CercleFinance.com) – Crossject soars 10%, following the expansion of the geographic coverage of its December 2023 marketing agreement with an undisclosed partner for its emergency treatment of epileptic seizures, Zepizure.…
Crossject: adjusted cursor
By Hector Chaunu Published on 01/26/2024 at 3:02 p.m. The pharmaceutical company Crossject fell 1.5% to 5.20 euros, while Invest Securities adjusted its target…
Crossject engages Syneos Health for the commercial launch of ZEPIZURE® in the United States – 01/05/2024 at 08:45
Crossject, a specialty pharmaceutical company developing needle-free auto-injectors dedicated to emergency situations, has engaged Syneos Health, a fully integrated leader in biopharmaceutical laboratory services to engage in preparation for the…
Crossject: Syneos Health committed to Zepizure in the United States
(CercleFinance.com) – Crossject announces that it has hired Syneos Health, a biopharmaceutical laboratory services group, to prepare for the commercial launch in the United States of Zepizure, its innovative emergency…
Crossject: Syneos Health committed to Zepizure in the United States – 01/05/2024 at 08:55
(CercleFinance.com) – Crossject announces that it has hired Syneos Health, a biopharmaceutical laboratory services group, to prepare for the commercial launch in the United States of Zepizure, its innovative emergency…
Crossject: improved ESG score in the Gaïa ranking
(CercleFinance.com) – Crossject announces that it has improved its Gaïa rating in terms of ESG performance, with a score of 73/100 this year compared to 60 in 2022 and 46…
Crossject: license agreement!
By Arnaud Bives Published on 07/20/2023 at 08:09 (Boursier.com) — Crossject entered into a commercial agreement for Australia and New Zealand for…
Crossject: an appointment to the supervisory board – 06/02/2023 at 11:51
(CercleFinance.com) – Crossject announced Friday the entry to its supervisory board of Daniel Teper, a pharmaceutical industry executive based in the United States, with the objective of expanding into the…